Senior Executive Service (SES) Performance Review Board; Members, 48513 [2022-17039]
Download as PDF
<![CDATA[
48513
Federal Register / Vol. 87, No. 152 / Tuesday, August 9, 2022 / Notices
is notice that on July 14, 2022, Chattem
Chemicals, 3801 Saint Elmo Avenue,
Chattanooga, Tennessee 37409–1237,
applied to be registered as a bulk
manufacturer of the following basic
class(es) of controlled substance(s):
Controlled substance
Drug code
Gamma Hydroxybutyric Acid .................................................................................................................................................
Marihuana ..............................................................................................................................................................................
Tetrahydrocannabinols ..........................................................................................................................................................
4-Methoxyamphetamine ........................................................................................................................................................
Noroxymorphone ...................................................................................................................................................................
Amphetamine .........................................................................................................................................................................
Methamphetamine .................................................................................................................................................................
Lisdexamfetamine ..................................................................................................................................................................
Methylphenidate ....................................................................................................................................................................
Cocaine ..................................................................................................................................................................................
Codeine .................................................................................................................................................................................
Dihydrocodeine ......................................................................................................................................................................
Oxycodone .............................................................................................................................................................................
Hydromorphone .....................................................................................................................................................................
Ecgonine ................................................................................................................................................................................
Hydrocodone .........................................................................................................................................................................
Levorphanol ...........................................................................................................................................................................
Methadone .............................................................................................................................................................................
Methadone intermediate ........................................................................................................................................................
Morphine ................................................................................................................................................................................
Oripavine ...............................................................................................................................................................................
Thebaine ................................................................................................................................................................................
Oxymorphone ........................................................................................................................................................................
Noroxymorphone ...................................................................................................................................................................
Alfentanil ................................................................................................................................................................................
Remifentanil ...........................................................................................................................................................................
Sufentanil ...............................................................................................................................................................................
Tapentadol .............................................................................................................................................................................
Fentanyl .................................................................................................................................................................................
The company plans to manufacture
the listed controlled substances in bulk
for distribution and sale to its
customers. In reference to drug codes
7360 (Marihuana) and 7370
(Tetrahydrocannabinols), the company
plans to bulk manufacture these drugs
as a synthetic. No other activities for
these drug codes are authorized for this
registration.
Kristi O’Malley,
Assistant Administrator.
Valorie Findlater, Office of Human
Capital, by email at valorie.findlater@
nara.gov or by telephone at (301) 837–
3754.
BILLING CODE P
NATIONAL ARCHIVES AND RECORDS
ADMINISTRATION
[NARA 2022–059]
Senior Executive Service (SES)
Performance Review Board; Members
Office of Human Capital,
National Archives and Records
Administration.
ACTION: Notice of membership on the
SES Performance Review Board.
jspears on DSK121TN23PROD with NOTICES
AGENCY:
Notice is hereby given of the
appointment of members of the National
Archives and Records Administration
(NARA) Performance Review Board
(PRB). The members of the PRB for the
SUMMARY:
18:04 Aug 08, 2022
Applicable Date: This
appointment is effective on August 9,
2022.
DATES:
FOR FURTHER INFORMATION CONTACT:
[FR Doc. 2022–17011 Filed 8–8–22; 8:45 am]
VerDate Sep<11>2014
National Archives and Records
Administration are: William J. Bosanko,
Chief Operating Officer; Micah M.
Cheatham, Chief of Management and
Administration; and Valorie F.
Findlater, Chief Human Capital Officer.
These appointments supersede all
previous appointments.
Jkt 256001
The
authority for this notice is 5 U.S.C.
4314(c), which also requires each
agency to establish, in accordance with
regulations prescribed by the Office of
Personnel Management, one or more
SES Performance Review Boards. The
Board shall review the initial appraisal
of a senior executive’s performance by
the supervisor and recommend final
action to the appointing authority
regarding matters related to senior
executive performance.
SUPPLEMENTARY INFORMATION:
Debra Steidel Wall,
Acting Archivist of the United States.
[FR Doc. 2022–17039 Filed 8–8–22; 8:45 am]
BILLING CODE 7515–01–P
PO 00000
Frm 00063
Fmt 4703
Sfmt 4703
2010
7360
7370
7411
9145
1100
1105
1205
1724
9041
9050
9120
9143
9150
9180
9193
9220
9250
9254
9300
9330
9333
9652
9668
9737
9739
9740
9780
9801
Schedule
I
I
I
I
I
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
NUCLEAR REGULATORY
COMMISSION
[NRC–2022–0148]
Monthly Notice; Applications and
Amendments to Facility Operating
Licenses and Combined Licenses
Involving No Significant Hazards
Considerations
Nuclear Regulatory
Commission.
ACTION: Monthly notice.
AGENCY:
Pursuant to section 189.a.(2)
of the Atomic Energy Act of 1954, as
amended (the Act), the U.S. Nuclear
Regulatory Commission (NRC) is
publishing this regular monthly notice.
The Act requires the Commission to
publish notice of any amendments
issued, or proposed to be issued, and
grants the Commission the authority to
issue and make immediately effective
any amendment to an operating license
or combined license, as applicable,
upon a determination by the
Commission that such amendment
involves no significant hazards
consideration (NSHC), notwithstanding
the pendency before the Commission of
a request for a hearing from any person.
DATES: Comments must be filed by
September 8, 2022. A request for a
hearing or petitions for leave to
SUMMARY:
E:\FR\FM\09AUN1.SGM
09AUN1
]]>Agencies
[Federal Register Volume 87, Number 152 (Tuesday, August 9, 2022)]
[Notices]
[Page 48513]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2022-17039]
=======================================================================
-----------------------------------------------------------------------
NATIONAL ARCHIVES AND RECORDS ADMINISTRATION
[NARA 2022-059]
Senior Executive Service (SES) Performance Review Board; Members
AGENCY: Office of Human Capital, National Archives and Records
Administration.
ACTION: Notice of membership on the SES Performance Review Board.
-----------------------------------------------------------------------
SUMMARY: Notice is hereby given of the appointment of members of the
National Archives and Records Administration (NARA) Performance Review
Board (PRB). The members of the PRB for the National Archives and
Records Administration are: William J. Bosanko, Chief Operating
Officer; Micah M. Cheatham, Chief of Management and Administration; and
Valorie F. Findlater, Chief Human Capital Officer. These appointments
supersede all previous appointments.
DATES: Applicable Date: This appointment is effective on August 9,
2022.
FOR FURTHER INFORMATION CONTACT: Valorie Findlater, Office of Human
Capital, by email at [email protected] or by telephone at
(301) 837-3754.
SUPPLEMENTARY INFORMATION: The authority for this notice is 5 U.S.C.
4314(c), which also requires each agency to establish, in accordance
with regulations prescribed by the Office of Personnel Management, one
or more SES Performance Review Boards. The Board shall review the
initial appraisal of a senior executive's performance by the supervisor
and recommend final action to the appointing authority regarding
matters related to senior executive performance.
Debra Steidel Wall,
Acting Archivist of the United States.
[FR Doc. 2022-17039 Filed 8-8-22; 8:45 am]
BILLING CODE 7515-01-P
